Anti-V3 loop spectrotype in HIV-infected individuals during zidovudine therapy

Infection

Volumn 24, Issue 3, 1996, Pages 227-233

  Biselli, R ^a   Del Bono, V ^b   Anselmo, M ^c   Canessa, A ^b   Mazzarello, G ^b   D'Amelio, R ^a   Bassetti, D ^b  

^a DASRS   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c San Paolo Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CD4 ANTIGEN; ZIDOVUDINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305 321); HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PEPTIDE FRAGMENT;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; IMMUNOMODULATION; ISOELECTRIC FOCUSING; MALE; BLOOD; DENSITOMETRY; IMMUNOLOGY; MIDDLE AGED;

ADULT; DENSITOMETRY; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; ISOELECTRIC FOCUSING; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; ZIDOVUDINE;

EID: 0029661928     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01781097     Document Type: Article

References (23)

1. Mitsuya, H., Veinhold, K. J., Furman, P. A., St. Clair, M. H., Lehrman, S. N., Gallo, R. C., Bolognesi, D., Barry, D. W., Broder, S.: 3-azido 3 deoxythymidine (BW A509U): an antiviral agent that inhibits infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphoadenopathy-associaled virus in vitro. Proc. Natl. Acad. Sci. USA 85 (1985) 7096-7100.
2. Fischl, M. A., Richman, D. D., Grieco, M. H., and the AIDS Clinical Trial Group: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317 (1987) 185-191.
3. Yarchoan, R., Klecker, R. W., Weinhold, K. J., Markham, P. D., Lyerly, H. K., Durack, D. T., Gelmann, E., Lehrman, S. N., Blum, R. M., Barry, D. W.: Administration of 3′-azido-3′deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet i (1986) 575-580.
4. Volberding, P. A., Lagakos, S. W., Koch, M. A., and the AIDS Clinical Trial Group: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS clinical trials groups of the National Institute of Allergy and Infectious Diseases. N. Engl. J. Med. 322 (1990) 941-949.
5. Gerding, M. N., Schwurman, H. J., Bast, B. J. E. G., Borleffs, J. C. C.: Lymphocytes intrinsic lymphoproliferative capacity in patients with AIDS treated with zidovudine. AIDS 3 (1989) 671-673.
6. Rinaldo, C., Huang, X. L., Piazza, P., Armstrong, J., Rappocciolo, G., Pazin, G., McMahon, D., Gupta, P., Fan, Z., Zhang, Z., Ho, M.: Augmentation of cellular immune function during the early phase of zidovudine treatment of AIDS patients. J. Infect. Dis. 164 (1991) 638-645.
7. Clerici, M., Landay, A. L., Kessler, H. A., Phair, J. P., Venzon, D. J., Hendrix, C. W., Lucey, D. R., Shearer, G. M.: Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J. Infect. Dis. 166 (1992) 723-730.
8. Zamarchi, R., Panozzo, M., Del Mistro, A., Barelli, A., Borri, A., Amadori, A., Chieco-Bianchi, L.: B and T cell function parameters during zidovudine treatment of human immunodeficiency virus-infected patients. J. Infect. Dis. 170 (1994) 1148-1156.
9. Rusche, J. R., Javaherian, K., McDanal, C., Petro, J., Lynn, D. L., Grimaila, R., Langlois, A., Gallo, R. C., Arthur, L. O., Fischinger, P. J., Bolognesi, D. P., Putney, S. D., Matthews, T. J.: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. USA 85 (1988) 3198-3202.
10. Askonas, B., Williamson, A. R., Wright, B. E. G.: Selection of a single antibody-forming cell clone and its propagation in syngeneic mice. Proc. Natl. Acad. Sci. USA 67 (1970) 1398-1401.
11. Roos, R. P., Nalefski, E, A., Nitayaphan, S., Variakojis, R., Singh, K. K.: An isoelectric focusing overlay study of the humoral immune response in Theiler's virus demyelinating disease. J. Neuroimmunol. 13 (1987) 305-314.
12. Grimaldi, L. M. E., Roos, R. P., Devare, S. G., Robey, W. G., Robey, J. M., Robey, M. E., Apatoff, B. R. Lazzarin, A.: Restricted heterogeneity of antibody to gp120 and p24 in AIDS. J. Immunol. 141 (1988) 114-117.
13. D'Amelio, R. Biselli, R., Nisini, R., Matricardi, P. M., Aiuti, A., Mezzaroma, I., Pinter, E., Pontesilli, O., Aiuti, F.: Spectrotype of antigp120 antibodies remains stable during the course of HIV disease. J. Acquir. Immune Defic. Syndr. 5 (1992) 930-935.
14. Redfield, R. R., Birx, D. L., Ketter, N., Tramont, E., Polonis, V., Davis, C., Brundage, J. F., Smith, G., Johnson, S., Fowler, A., Wierzba, T., Shafferman, A., Volvovitz, F., Oster, C., Burke, D. S. and the Military Medical Consortium for Applied Retroviral Research: A Phase 1 evaluation of the safety and immunogenicity of vaccination with recombinant gp 160 in patients with early human immunodeficiency virus infection. N. Engl. J. Med. 324 (1991) 1677-1684.
15. Biselli, R., Loomis, L. D., Del Bono, V., Burke, D. S., Redfield, R. R., Birx, D. L.: Immunization of HIV-infected patients with rgp 160: modulation of anti-rgp 120 antibody spectrotype. J. Acquir. Immune Defic. Syndr. 7 (1994) 1016-1024.
16. Cao, Y., Ho, D. D., Todd, J., Kokka, R., Urdea, M., Lifson, J. D., Piatak, M., JR, Chen, S., Hahn, B. H., Saag, M. S., Shaw, G. M.: Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retroviruses 11 (1995) 353-361.
17. 3. Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., 1995, abstr. 173.
18. Zimmermann, F., Biesert, L., von Briesen, H., Wegner, R., Helm, E. B., Staszewski, S., Rubsamen-Waigmann, H.: Development of HIV-variants with higher resistance against AZT under treatment with AZT. IV. International Conference on AIDS, Stockholm, 1988, abstr. 3656.
19. Larder, B. A., Darby, G., Richman, D. D.: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243 (1989) 1731-1734.
20. Baur, A., Vornhagen, R., Korn, K., Sonneborn, H. H., Eberlein, B., Harrer, T., Brockhaus, W., Hahn, G.: Viral culture and P24 antigenemia of human immunodeficiency virus (HIV)-infected individuals correlated with antibody profiles determined with recombinant polypeptides of all HIV-1 open-reading frames. J. Infect. Dis. 165 (1992) 419-426.
21. Amadori, A., De Silvestro, G., Zamarchi, R., Veronese, M. L., Mazza, M. R., Schiavo, G., Panozzo, M., De Rossi, A., Ometto, L., Mous, J., Barelli, A., Borri, A., Salmaso, L., Chieco-Bianchi, L.: CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients. J. Immunol. 148 (1992) 2709-2716.
22. Bagnarelli, P., Menzo, S., Manzin, A., Giacca, M., Varaldo, P. E., Clementi, M.: Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. J. Virol. Methods 34 (1991) 89-95.
23. Pachl, C., Todd, J. A., Kern, D. G., Sheridan, P. J., Fong, S., Stempien, M., Hoo, B., Besemer, D., Yeghiazarian, T., Irvine, B., Kolberg, J., Kokka, R., Neuwald, P., Urdea, M. S.: Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. AIDS 8 (1995) 446-454.